IRIDEX Corporation (IRIX)

IRIDEX Corporation is a healthcare company focused on ophthalmic medical technology. The company develops therapeutic laser systems, delivery devices, and consumable instruments used in the treatment of sight-threatening eye diseases. Its product range includes laser consoles for glaucoma and retinal disorders, as well as photocoagulation systems used in procedures involving diabetic retinopathy, macular holes, retinal tears, and retinal detachments. IRIDEX also supplies delivery devices and probes designed for use in office-based and surgical eye care settings. The company sells its products to ophthalmologists, hospitals, surgical centers, research and teaching institutions, government installations, veterinary practices, and office clinics. It serves customers in the United States and through distributors in international markets across Europe, the Middle East, Africa, Asia/Pacific, and the Americas. Founded in 1989 and headquartered in Mountain View, California, the company was previously known as IRIS Medical Instruments, Inc.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-IRIX
$0.78
16.0% Upside
Fair
$2.75
310.4% Upside
Bargain
Fair
0.0%
November 17, 2026
0.2x
11.535 M
17.012 M
18.7%
29.7%
-2.7
56.4%
Valuation • Fair Value

IRIDEX Corporation (NASDAQ-IRIX) Fair Value by Valuation Model

Review the available estimates for IRIDEX Corporation (NASDAQ-IRIX), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$0.78

Estimated upside of 16.0% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$1.21

Discounted cash flow valuation reference.

Comps Fair Value

$0.70

Comparable-company valuation reference.

Analyst Price Target

$2.75

Analysts imply upside of 310.4%.

How to read these valuation models

Use the 5 available valuation references for IRIDEX Corporation (NASDAQ-IRIX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for IRIDEX Corporation (NASDAQ-IRIX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

51.573 M

Current operating scale indicator.

Revenue Forecast

52.521 M

Forward revenue estimate.

EBITDA

-2.604 M

Current operating profitability reference.

EBITDA Forecast

1.256 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review IRIDEX Corporation (NASDAQ-IRIX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for IRIDEX Corporation (NASDAQ-IRIX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.80

No elevated caution signal from this screen.

Altman Z-Score

-2.7

Lower score that deserves closer risk review.

FCF / Net Income

56.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for IRIDEX Corporation (NASDAQ-IRIX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for IRIDEX Corporation (NASDAQ-IRIX)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 17, 2026

Days to Earnings

60

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for IRIDEX Corporation (NASDAQ-IRIX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

IRIDEX Corporation (NASDAQ-IRIX) Stock Forecast & Technical Outlook

Review IRIDEX Corporation (NASDAQ-IRIX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for IRIDEX Corporation (NASDAQ-IRIX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Buy

The 1-hour technical read for IRIDEX Corporation (NASDAQ-IRIX) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for IRIDEX Corporation (NASDAQ-IRIX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for IRIDEX Corporation (NASDAQ-IRIX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for IRIDEX Corporation (NASDAQ-IRIX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for IRIDEX Corporation (NASDAQ-IRIX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, IRIDEX Corporation (NASDAQ-IRIX) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ Fast Investor Answers

IRIDEX Corporation (NASDAQ-IRIX) Stock FAQ

Data-supported answers about IRIDEX Corporation (NASDAQ-IRIX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.78
Estimated upside 16.0%
Valuation Rating
Undervalued
Estimated upside of 16.0%
Analyst Target
$2.75
Implied upside 310.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for IRIDEX Corporation (NASDAQ-IRIX) is $0.78. This implies an estimated upside of 16.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 16.0% versus the current market price.

The available analyst price target for IRIDEX Corporation (NASDAQ-IRIX) is $2.75. The analyst target implies estimated upside of 310.4%.

The current financial health read for IRIDEX Corporation (NASDAQ-IRIX) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for IRIDEX Corporation (NASDAQ-IRIX) is November 17, 2026.

The latest available data indicates no current dividend yield for IRIDEX Corporation (NASDAQ-IRIX).

The current market capitalization listed for IRIDEX Corporation is 11.535 M.

The current enterprise value listed for IRIDEX Corporation is 17.012 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for IRIDEX Corporation is NASDAQ-IRIX, and the stock is listed on NASDAQ.

IRIDEX Corporation (NASDAQ-IRIX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for IRIDEX Corporation is 18.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for IRIDEX Corporation is 29.7%. Free float helps investors understand how much of the share base is available for public trading.